Skip to content
azasetron

Structure via PubChem · Public domain (PubChem)

EntityQ4832285· pop 8· linked from 1,400 articles

Also known as Y-25130

Azasetron is an antiemetic which acts as a 5-HT3 receptor antagonist, pKi = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi.

In the Vinony graph

Vinony's link graph records 1,400 inbound references to azasetron, and connects out to N-methylserotonin, glaucine and 5-carboxamidotryptamine.

It sits within the topics 5-HT3 antagonists, Chemical pages without DrugBank identifier and Chlorobenzene derivatives.

Vinony links it to 7 Wikipedia language editions.

Chemical data

Formula
C17H20ClN3O3
Molecular weight
349.8 g/mol
IUPAC name
N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 2
Molecule type
Small molecule
Indications
hearing loss

via ChEMBL · EBI

Wikidata facts

Mass
349.119319
Show 3 more facts
chemical formula
C₁₇H₂₀ClN₃O₃
canonical SMILES
CN1C(=O)COC2=C1C=C(C=C2C(=O)NC3CN4CCC3CC4)Cl
Commons category
Azasetron
Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

1 sections
Contents
  • References

Azasetron is an antiemetic which acts as a 5-HT3 receptor antagonist, pKi = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi.

Arazasetron besylate (SENS-401) is an investigational drug formulation containing exclusively the R-enantiomer of azasetron. The compound has been studied to prevent hearing loss related to sudden sensorineural hearing loss (SSNHL), acoustic trauma, and cisplatin-induced ototoxicity.

Excerpted from Wikipedia’s “azasetron” article, available under the CC BY-SA 4.0 licence.

Available in 7 languages

via Wikidata sitelinks · CC0

Connections

Categories